Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
Abroad (travel likely)RecruitingPHASE2
Conditions
Relapsed Cancer · Refractory Multiple Myeloma · Multiple Myeloma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Massachusetts General Hospital, Boston, Massachusetts, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study leads
Andrew Yee, MD
Principal Investigator
Massachusetts General Hospital